Saccharo Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$11.5M
- Investors
-
8
Saccharo General Information
Description
Operator of an immuno-oncology company intended to develop various cancer therapies. The company's therapies utilize a novel polysaccharide-based immune-shielding pathway, enabling healthcare providers to treat patients and cure them.
Contact Information
Website
www.saccharo.comCorporate Office
- 6401 Chelton Drive
- Oakland, CA 94611
- United States
Corporate Office
- 6401 Chelton Drive
- Oakland, CA 94611
- United States
Saccharo Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 16-Aug-2022 | $11.5M | Completed | Pre-Clinical Trials |
Saccharo Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed |
Saccharo Patents
Saccharo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026015903-A1 | De-n-acetylated polysialic acid (dpsa) binding agent conjugates and mel'hod of using same | Pending | 12-Jul-2024 | ||
| JP-2026524032-A | De-n-acetylated polysialic acid (dpsa) binders, conjugates, and methods of using the same. | Pending | 12-Jul-2023 | ||
| AU-2024287644-A1 | De-n-acetylated polysialic acid (dpsa) binding agent, conjugates, and method of using same | Pending | 12-Jul-2023 | ||
| EP-4743124-A1 | De-n-acetylated polysialic acid (dpsa) binding agent, conjugates, and method of using same | Pending | 12-Jul-2023 | ||
| WO-2025015281-A1 | De-n-acetylated polysialic acid (dpsa) binding agent, conjugates, and method of using same | Inactive | 12-Jul-2023 | A61K47/68031 |
Saccharo Signals
Saccharo Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Foreview Ventures | Family Office | Minority | ||
| K2X | Venture Capital | Minority | ||
| Life Science Angels | Angel Group | Minority | ||
| MVP Funds by Moore Venture Partners | Venture Capital | Minority | ||
| Rivermount VC Fund | Venture Capital | Minority |
Saccharo FAQs
-
When was Saccharo founded?
Saccharo was founded in 2018.
-
Where is Saccharo headquartered?
Saccharo is headquartered in Oakland, CA.
-
What is the size of Saccharo?
Saccharo has 5 total employees.
-
What industry is Saccharo in?
Saccharo’s primary industry is Drug Discovery.
-
Is Saccharo a private or public company?
Saccharo is a Private company.
-
What is the current valuation of Saccharo?
The current valuation of Saccharo is .
-
What is Saccharo’s current revenue?
The current revenue for Saccharo is .
-
How much funding has Saccharo raised over time?
Saccharo has raised $11.5M.
-
Who are Saccharo’s investors?
Foreview Ventures, K2X, Life Science Angels, MVP Funds by Moore Venture Partners, and Rivermount VC Fund are 5 of 8 investors who have invested in Saccharo.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process